Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CAPN1 antisense RNA 1 (CAPN1-AS1)
- Target
- CAPN1-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Non-coding RNA
01
Overview
CAPN1 antisense RNA 1 (CAPN1-AS1) is a human long non-coding RNA gene situated on the opposite strand of the protein-coding gene CAPN1[1][7]. Like other antisense RNAs, CAPN1-AS1 transcripts overlap with the sense (coding) gene and modulate its expression through various mechanisms, including transcriptional interference and chromatin modification. Antisense RNAs often influence pre-mRNA processing, stability, and translation of their sense gene partners[2][7]. The physiological and pathological roles of CAPN1-AS1 remain largely unknown, but deregulation of antisense lncRNAs can potentially contribute to disease processes by altering the expression and regulation of critical protein-coding genes, including CAPN1[7]. No direct disease associations or drug interactions are documented for CAPN1-AS1 at this time.
- Other names
- CAPN1-AS1
02
Mechanism of action
Not applicable. There are no drugs acting directly on CAPN1-AS1; however, synthetic antisense oligonucleotides (ASOs) can theoretically modulate antisense lncRNAs if designed for this purpose.
03
Biological functions
Regulation of gene expression via antisense mechanisms (primarily affecting the sense gene CAPN1)Potential involvement in chromatin organization and transcriptional regulation
04
Disease associations
Other. Deregulation of antisense RNAs, including lncRNAs like CAPN1-AS1, has been associated generally with diseases such as cancer, cardiovascular disease, and diabetes by affecting their sense genes, though no specific disease association is currently confirmed for CAPN1-AS1 itself.
05
Safety considerations
none specifically documented. As a non-coding RNA, general safety concerns would only arise if targeted therapeutically, such as off-target effects of antisense therapies
Beyond the preview
Go deeper on CAPN1 antisense RNA 1 (CAPN1-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAPN1 antisense RNA 1 (CAPN1-AS1).